Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03499899 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT03499899 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT03499899, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced triple-negative breast cancer (TNBC) in first or second line therapy.
Interventions
- DRUG Carboplatin
- DRUG PDR001
- DRUG LAG525
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2021-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03499899
The ClinicalTrials.gov registry entry for NCT03499899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT03499899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03499899 about?
NCT03499899 is a clinical study titled "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer". The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced triple-negative breast cancer (TNBC) in first or second line therapy.
What is the current status of trial NCT03499899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2018-07-02. Estimated completion is 2021-11-24.
What interventions are being tested in trial NCT03499899?
The interventions under investigation include: Carboplatin (DRUG), PDR001 (DRUG), LAG525 (DRUG).
Who is sponsoring clinical trial NCT03499899?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.